PACLITAXEL BY 3-H INFUSION AND CARBOPLATIN IN ANTHRACYCLINE-RESISTANTADVANCED BREAST-CANCER - A PHASE-II STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP

37 patients with advanced breast cancer resistant to anthracyclines we re treated with paclitaxel 200 mg/m(2) by 3-h infusion and carboplatin at an area under the curve of 7 mg.min/ml every 4 weeks with G-CSF su pport. There were 5 (14%, 95% CI 3-25%) complete and 11 (30%, 95% CI 1 5-45%) partial responders. Median duration of response was 11.5 months (range 5.2-16.8+), median time to progression 8 months (range 0.26-16 .8+) and median survival 12 months (range 0.5-19.6+). Grade 3-4 leucop enia (27%), thrombocytopenia (10%) and diarrhoea (5%) were noted. In c onclusion, the combination of paclitaxel and carboplatin is active and well tolerated in patients with advanced breast cancer resistant to a nthracyclines. (C) 1997 Published by Elsevier Science Ltd.